Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 23: Inflammatory Risk from Statin-Treated Patients
Author(s): Paul M Ridker Added: 1 year ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more

Prevention & Chronic Conditions
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 1 year ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 5 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 6 months ago

Prevention & Chronic Conditions

MI/ACS
ESC 23: LODESTAR Trial
Author(s): Myeong-Ki Hong Added: 1 year ago
ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was a randomized, open-label multicenter trial that aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary prevention of coronary artery disease. 4400 coronary artery disease… View more

Prevention & Chronic Conditions
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 month ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
AHA 23: 3 Trials That Will Change My Practice
Author(s): Purvi Parwani Added: 1 year ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac… View more

Guidelines & Statements

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Clinical Professor and Director of Preventive Cardiology
Jane Armitage
Research Area(s) / Expertise: Job title: Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
Jane Armitage, FRCP, FFPH, OBE, is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine and also Director of Training and Career Development for the Nuffield Department of Population Health. She works on the epidemiology of cardiovascular disease and has led large-scale randomized controlled trials. Dr Armitage is Chief Investigator for the BHF-supported… View more